ReviewInternational journal of molecular sciences2020
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 86 citations in OpenAlex.
- Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study.Frontiers in medicine · 2026Article
- A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes.Frontiers in endocrinology · 2025Article
- New-onset diabetes mellitus in patients with COVID19 infection admitted to a tertiary care hospital: A single-center experience.Pakistan journal of medical sciences · 2024Article
- [Predictive value of C-reactive protein on hospital admission and mechanical ventilation requirement in adults hospitalized for COVID-19]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2024Article
- A Review on Role of Inflammation in Coronavirus Disease.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Cytokine storm and translating IL-6 biology into effective treatments for COVID-19.Frontiers of medicine · 2023Review
- Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID-19 patients with pre-existing comorbidities.Clinical and translational science · 2023Article
- The Local Anaesthetic Procaine Prodrugs ProcClusterInternational journal of molecular sciences · 2023Article
- A rare case of newly diagnosed diabetes mellitus following COVID-19 infection.Journal of clinical and translational endocrinology case reports · 2023Article
- SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.Cell biology international · 2022Review
- The Association between SARS-CoV-2 Infection and Diabetic Ketoacidosis in Patients with New-Onset Diabetes: A Retrospective Study from a Diabetic Center in Saudi Arabia.Pediatric reports · 2022Article
- Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy.BMC nephrology · 2022Observational
- Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK.PLoS medicine · 2022Article
- A Journey into the Clinical Relevance of Heme Oxygenase 1 for Human Inflammatory Disease and Viral Clearance: Why Does It Matter on the COVID-19 Scene?Antioxidants (Basel, Switzerland) · 2022Review
- Review
- COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.Frontiers in immunology · 2022Review
- COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.Frontiers in endocrinology · 2022Review
- Newly Diagnosed Diabetes in Patients with COVID-19: Different Types and Short-Term Outcomes.Tropical medicine and infectious disease · 2021Article
- Harnessing immunological targets for COVID-19 immunotherapy.Future virology · 2021Review
- Racial differences in dietary choices and their relationship to inflammatory potential in childbearing age women at risk for exposure to COVID-19.Nutrition research (New York, N.Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.